検索
Silence Therapeutics PLC
SLNウォッチリストに追加
10.390USD
-0.110-1.05%
終値 07/02, 13:00（ET）15分遅れの株価
490.76M時価総額
損失額直近12ヶ月PER
詳細情報 Silence Therapeutics PLC 企業名
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Silence Therapeutics PLCの企業情報
企業コードSLN
会社名Silence Therapeutics PLC
上場日Jan 05, 2010
最高経営責任者「CEO」Tooman (Craig A)
従業員数116
証券種類Depository Receipt
決算期末Jan 05
本社所在地72 Hammersmith Road
都市LONDON
証券取引所NASDAQ OMX - NASDAQ BASIC
国United Kingdom
郵便番号W14 8TH
電話番号442034576900
ウェブサイトhttps://www.silence-therapeutics.com/
企業コードSLN
上場日Jan 05, 2010
最高経営責任者「CEO」Tooman (Craig A)
Silence Therapeutics PLCの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
よくある質問
Silence Therapeutics PLCの上位5名の株主は誰ですか？
Silence Therapeutics PLCの上位5名の株主は以下のとおりです。Mr. David Jakob (Dave) Lemus, CPA
Silence Therapeutics PLC（SLN）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Silence Therapeutics PLCの株式を保有している機関は147社あり、保有株式の総市場価値は約19.17Mで、全体の40.59%を占めています。2025Q4と比較して、機関の持ち株は-12508865.00増加しています。